SAN DIEGO --(BUSINESS WIRE)--Dec. 3, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien , J.D., as general counsel
SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal
Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO --(BUSINESS WIRE)--Nov. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate
SAN DIEGO --(BUSINESS WIRE)--Oct. 24, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new
SAN DIEGO --(BUSINESS WIRE)--Oct. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s novel once-weekly
SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel
Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO --(BUSINESS WIRE)--May 23, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel
New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates SAN DIEGO --(BUSINESS WIRE)--May 21, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
SAN DIEGO , May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and
Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO --(BUSINESS WIRE)--Apr. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing
Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO , March 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 Company to host conference call today at 8:00 a.m. ET / 5:00 a.m.
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44 th Annual Meeting of the European
SAN DIEGO , March 01, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company’s board of directors. Ms.
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017 , and provided an update on its
Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including
Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a
